Measurement of AMPA receptor density in patients with depression and bipolar disorder: a PET study
- Conditions
- Depressionbipolar disorder
- Registration Number
- JPRN-UMIN000039357
- Lead Sponsor
- Department of Physiology,Yokohama City University, School of Medicie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
(1) being pregnant or breast-feeding, or wishing to become pregnant, (2) being sensitive to alcohol, (3) comorbidity of serious neurological illness, (4) history of epilepsy, (5) use of perampanel or topiramate within 4 weeks, (6) history of substance use disorder for the past 6 months, (7) positive result on urine screening of substances that cause dependence, (8) having a metal object or pace maker in the body, (9) inappropriate size of head, neck, or body for MRI scan, (10) having large tatoo, (11) suffering from serious claustrophobia, (12) presence of significant brain anomaly, (13) abnormal lab results as follows: serum creatinine level of >=1.5, AST of >=150, or ALT of >=150, (14) having participated in any clinical trial that included the use of unapproved nuclear test within 6 months, (15) having participated in any other clinical trial that included intervention, (16) being judged to be inappropriate for participation by a study medical doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AMPA receptor density and mood symptom scores in each of depression and bipolar disorder
- Secondary Outcome Measures
Name Time Method Accuracy of differentiation of depression and bipolar disorder with the data collected in this study by using optimized machine learning program Differences in AMPA receptor density in each voxel between depression and bipolar disorder Adverse events during 7 days after administration of [11C]K-2